OverviewSuggest Edit

    Transgene (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The Company’s two lead clinical-stage programs are: TG4010 for non-small cell lung cancer and Pexa-Vec for liver cancer. The Company has several other programs in clinical and pre-clinical development. Transgene is based in Strasbourg, France, and has additional operations in Lyon, as well as satellite offices in China and the U.S.
    HQIllkirch, FR

    Latest Updates

    Employees (est.) (Feb 2019)134
    Job Openings3

    Key People/Management at Transgene

    Juan Pedro R. Serrate

    Juan Pedro R. Serrate


    Transgene Office Locations

    Transgene has offices in Illkirch, Lyon, Cambridge and Shanghai
    Shanghai, CN
    Rm 508, Building 2 4633, Pusan Road Kangqiao Industrial Park, Pudong Shanghai
    Lyon, FR
    321 Avenue Jean Jaurès
    Cambridge, US
    355 Main St #802
    Show all (4)

    Transgene Online and Social Media Presence

    Embed Graph

    Transgene News and Updates

    AstraZeneca ties up with France's Transgene to develop viral immunotherapies

    British drugmaker AstraZeneca Plc and French biopharmaceutical firm Transgene SA entered into an agreement on Thursday to co-develop five cancer-killing viral immunotherapies.

    BioInvent and Transgene Extend Their Collaboration to Develop Multifunctional Oncolytic Viruses for the Treatment of Solid Tumors

    LUND, Sweden and STRASBOURG, France, March 26, 2019 /PRNewswire/ -- BioInvent International AB (OMXS: BINV), a biotech company focused on the discovery and development of novel immuno-regulatory antibodies to treat cancer and Transgene (Euronext Paris: TNG), a biotech company that designs ...

    Gene Therapy Market to Set Phenomenal Growth from 2018 to 2026 Estimated by Global Top Players GlaxoSmithKline plc, Bluebird Bio, Inc., Adaptimmune Therapeutics plc, Celgene Corporation, Shanghai Sunway Biotech Co. Ltd., Merck KGaA, Transgene SA

    #Summary: Summary This report includes market status and forecast of global and major regions, with the introduction of vendors, regions, product types and end industries; and this report counts product types and end industries in global and major regions. Posted via Industry Today. Follow us on Twi…

    GDR issue: Sebi lifts market ban on Transgene Biotek's 2 promoters, director

    Sebi has revoked market ban against Transgene Biotek's two promoters and a director, in a case related to alleged diversion of funds by the pharma firm through issuance of GDRs, as the regulator did not come across any adverse findings against them. According to Sebi, there are no adverse findings a…
    Show more

    Transgene Frequently Asked Questions

    • Who are Transgene key executives?

      Transgene's key executives are Juan Pedro R. Serrate.

    • How many employees does Transgene have?

      Transgene has 134 employees.

    • Who are Transgene competitors?

      Competitors of Transgene include Innate Pharma, Magenta Therapeutics and Synthace.

    • Where are Transgene offices?

      Transgene has offices in Illkirch, Lyon, Cambridge and Shanghai.

    • How many offices does Transgene have?

      Transgene has 4 offices.